Market Snapshot

BSE Sensex: 81118.6 -0.70%
BSE 500: 35946.69 -0.57%
BSE 200: 11252.01 -0.61%
BSE 100: 25940.81 -0.65%
BSE MidCap: 45681.28 -0.32%
BSE SmallCap: 53370.29 -0.30%
BSE BANKEX: 62570.44 -1.01%
BSE IT: 37839.04 -0.09%
Nifty 50: 24718.6 -0.68%
Nifty 500: 22906.2 -0.61%
Nifty 200: 13825.4 -0.65%
Nifty 100: 25331.35 -0.71%
Nifty Midcap 100: 58227.45 -0.37%
Nifty Small 100: 18374.8 -0.49%
Nifty IT: 38469.25 0.02%
Nifty PSU Bank: 6934.85 -1.18%

News:

Lemon Tree Hotels signs new pr...
Adani Enterprises arm incorpor...
Syngenes Bengaluru-based facil...
NATCO Pharmas Hyderabad-based ...
Arkade Developers acquires 6.2...

Concord Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

13 Jun 2025 | 04:14 PM

2,109.70

46.10 (2.23%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

46.03%

Return (1Y)

Beaten Nifty 500 by 42.26%
More Volatile

3.38%

Standard Deviation (1Y)

Higher than Nifty 500 by 2.44%
Consistent Performer

9/12

Months

beaten Nifty 500
AxisDirect View

No View

52 Week High-Low

2,664

1,345

News & Announcements

Board of Concord Biotech recommends final dividend
16 days ago

Board of Concord Biotech recommends final dividend

30 - May - 2025 12:00 | 16 days ago

Concord Biotech announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 10.7 per equity Share (i.e. 1070%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News

Concord Biotech consolidated net profit rises 47.75% in the March 2025 quarter

16 days ago

Concord Biotech to announce Quarterly Result
22 days ago

Concord Biotech to announce Quarterly Result

24 - May - 2025 12:00 | 22 days ago

Concord Biotech will hold a meeting of the Board of Directors of the Company on 29 May 2025.
Powered by Capital Market - Live News
Concord Biotech gets US FDA nod for marketing multiple sclerosis drug Teriflunomide
67 days ago

Concord Biotech gets US FDA nod for marketing multiple sclerosis drug Teriflunomide

09 - Apr - 2025 12:00 | 67 days ago

Teriflunomide tablets are used for the treatment of patients with relapsing forms of multiple sclerosis.
This approval reinforces our capability in successfully developing and commercializing a differentiated product portfolio for the U.S. market, Concord Biotech said in a statement.
According to IQVIA, the market size of Teriflunomide tablets is approximately $402 million in the US, and the global market size is approximately $908 million, indicating significant opportunities for expansion in the US and the global market.
Concord Biotech is involved in manufacturing fermentation and semi-synthetic biopharmaceutical APIs with immunosuppressants as its key therapeutic segment.
The company's consolidated net profit fell 2% to Rs 75.9 crore in Q3 FY25 compared with Rs 77.6 crore in Q3 FY24. Revenue from operations increased 1% year-on-year (YoY) to Rs 244.2 crore in Q3 FY25.
The scrip shed 0.17% to currently trade at Rs 1595.10 on the BSE.

Powered by Capital Market - Live News

Price vs Volume

1D
5D
1M
3M
1Y
3Y
5Y
MAX

Stock Trivia

FII shareholding in Concord Biotech Ltd has increased by 12.2% since past 3 Months
MF shareholding in Concord Biotech Ltd has increased by 6.01% since past 3 Months
FII shareholding in Concord Biotech Ltd has increased by 44.25% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

×

Online trading for clients based in USA and Canada is restricted. You can continue placing orders through mapped dealers offline

OK

vV5.0.0.6-60